Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas. Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. // Clinical and Translational Medicine. – 2026. – DOI: 10.1002/ctm2.70890. – URL: https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70890?af=R
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, & Stefani N. Thomas (2026). Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70890
Jesenia M. Perez, et al. “Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer.” Clinical and Translational Medicine, 2026. doi:10.1002/ctm2.70890.
@article{Perez2026,
title = {Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer},
author = {Perez, Jesenia M. and Hwang, Justin and Erickson, Britt K. and Thomas, Stefani N.},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70890},
url = {https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70890?af=R}
}
Nature Biomedical Engineering, Published online: 18 November 2026; doi:10.1038/s41551-026-01843-z Tumour-associated mucins induce the disassembly of a designer PEGylated paclitaxel-conjugated nanomedicine into small unimers that escape...